Abstract 1490P
Background
Tumor necrosis factor (TNF-α) has anticancer activity. Tumors neutralize TNF-α by shedding excess soluble TNF receptors (sTNF-Rs) in the tumor microenvironment preventing TNF-α from binding to tumor membrane bound sTNF-Rs, triggering cell death pathways. Removal of sTNF-Rs via apheresis liberates the anticancer effects of TNF-α alone or with anticancer agents.
Methods
Protocol CP7-008 [NCT04690686] evaluated LW-02 Column Immunopheresis® (‘LW-02 CI’) in advanced (Stages IIIB/IV) squamous or adenocarcinoma NSCLC patients (pts), who progressed 1or 2 line(s) of treatment (1st-line with a platinum salt). Sixteen (16) pts were assigned to 1 of 3 arms to receive LW-02 CI 3x/week: with atezolizumab (Arm 1, n=7), with paclitaxel (Arm 2, n=3) or as monotherapy (Arm 3, n=6; pts progressed 2 lines, or 1 but not suitable for Arm 1) for 16 weeks. Clinically stable and/or objectively improved pts could receive extended therapy.
Results
Safety and tumor burden changes were evaluated in two groups—pts that had at least 1 LW-02 CI treatment (‘ITT’) and pts treated ≥4 weeks (≥4 wks). Pts’ tumor burden was assessed via RECIST 1.1 (or iRECIST if appropriate). After 644 LW-02 CI procedures, 373 AEs (including 22 SAEs) were reported; 18 AEs (14.8%), including 3 SAEs (13.6%), had a causal relationship to treatment with the LW-02 Column. All were Grades 1 or 2, except for 2 Grade 3 SAEs. All resolved, and none required treatment discontinuation. For tumor burden, the best overall response was stable disease (11 pts), durable for ≥8 wks. Other endpoints were duration of treatment (DoT), overall survival (OS), disease control rate (DCR) and progression free survival (PFS). The results are summarized for both groups below.
Table: 1490P
Median DoT, OS, DCR and PFS
Endpoint (mos) | Overall | Arm 1 | Arm 2 | Arm 3 | ||||
ITT | ≥4 wks | ITT | ≥4 wks | ITT | ≥4 wks | ITT | ≥4 wks | |
DoT | 4.1 | 4.7 | 4.3 | 4.7 | 5.4 | 5.4 | 3.0 | 3.5 |
OS | 9.9 | 11.1 | 16.5 | 17.0 | 9.5 | 9.5 | 7.7 | 10.2 |
PFS | 4.1 | 5.2 | 4.0 | 4.0 | 7.7 | 7.7 | 5.5 | 5.8 |
DCR % | 68.8 | 84.6 | 57.1 | 80.0 | 100.0 | 100.0 | 66.7 | 80.0 |
Conclusions
LW-02 CI alone or combined with chemo- or immunotherapy appears safe with clear anticancer efficacy signals in treating advanced NSCLC. These results, when compared with data from existing therapies, warrant further investigation.
Clinical trial identification
NCT04690686.
Editorial acknowledgement
Legal entity responsible for the study
Immunicom Inc.
Funding
Immunicom Inc.
Disclosure
M. Bozkurt, D. Gökhan, M. Teomete: Financial Interests, Institutional, Principal Investigator: Immunicom Inc.. C. Turam: Financial Interests, Institutional, Coordinating PI: Immunicom Inc.. L. Florin: Financial Interests, Institutional, Member of Board of Directors: Immunicom. A. Ostrowski: Financial Interests, Institutional, Officer, Employee: Immunicom. R. Segal, V. Manax: Financial Interests, Institutional, Member of Board of Directors: Immunicom.
Resources from the same session
1523P - Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
Presenter: Mustapha Tehfe
Session: Poster session 21
1524P - First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C
Presenter: Lin Shen
Session: Poster session 21
1526P - Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1
Presenter: Zev Wainberg
Session: Poster session 21
1527P - Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification
Presenter: Jiajia Yuan
Session: Poster session 21
1528P - A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Presenter: Daniel Olson
Session: Poster session 21
1529P - Tislelizumab plus chemotherapy sequential neo-chemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)
Presenter: Wenwu He
Session: Poster session 21
1530P - Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and GLOW
Presenter: Florian Lordick
Session: Poster session 21
1532P - Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy
Presenter: Shun Yamamoto
Session: Poster session 21